Jim Simons Iveric Bio, Inc. Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$26.24 - $39.63 $348,992 - $527,079	13,300 Added 7.01%	203,000 $7.99 Million
Q1 2023 May 12, 2023	BUY	$18.67 - $24.56 $3.29 Million - $4.33 Million	176,100 Added 1294.85%	189,700 $4.62 Million
Q4 2022 Feb 13, 2023	BUY	$17.24 - $23.95 $234,463 - $325,720	13,600 New	13,600 $291,000
Q4 2021 Feb 11, 2022	SELL	$13.83 - $18.78 $3.43 Million - $4.66 Million	-248,300 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$7.07 - $17.5 $1.76 Million - $4.35 Million	248,300 New	248,300 $4.03 Million
Q4 2020 Feb 10, 2021	SELL	$5.65 - $7.66 $1.29 Million - $1.75 Million	-228,180 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$4.01 - $6.29 $3.58 Million - $5.62 Million	-893,200 Reduced 79.65%	228,180 $1.29 Million
Q2 2020 Aug 13, 2020	SELL	$3.06 - $6.6 $359,856 - $776,160	-117,600 Reduced 9.49%	1,121,380 $5.72 Million
Q1 2020 May 14, 2020	BUY	$2.83 - $8.44 $505,721 - $1.51 Million	178,700 Added 16.85%	1,238,980 $4.26 Million
Q4 2019 Feb 13, 2020	SELL	$0.93 - $8.58 $128,316 - $1.18 Million	-137,975 Reduced 11.51%	1,060,280 $9.1 Million
Q3 2019 Nov 13, 2019	SELL	$1.09 - $1.29 $38,418 - $45,467	-35,246 Reduced 2.86%	1,198,255 $1.34 Million
Q2 2019 Aug 12, 2019	BUY	$1.21 - $1.48 $1.49 Million - $1.83 Million	1,233,501 New	1,233,501 $1.6 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.